LABTLakewood-Amedex Biotherapeutics Inc.
$2.69
$0.12
(4.60%)
Closed $2.73
$0.04
(1.47%)
After Hours
Mkt Cap$4.57M
Vol236,691.00
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance PR Newswire SARASOTA, Fla., July 7, 2026 Company...
PR Newswire
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a...
PR Newswire
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for High-Need Antimicrobial Infections
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for High-Need Antimicrobial Infections Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for...
PR Newswire
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum PR Newswire SARASOTA, Fla., June 16, 2026 SARASOTA, Fla., June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc...
PR Newswire
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers PR Newswire SARASOTA, Fla., May 27, 2026 Patent portfolio now includes 71...
PR Newswire
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces Positive Data for the...
PR Newswire
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for...
PR Newswire
Promising Penny Stocks To Watch Today - May 3rd
Esperion Therapeutics, SOBR Safe, JetBlue Airways, BigBear.ai, Lakewood-Amedex Biotherapeutics, Beyond Meat, and Direxion Daily AMD Bear 1X Shares are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares of small public companiesc...
MarketBeat
Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces Positive...
PR Newswire
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors PR Newswire SARASOTA, Fla...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest LABT News
ViewLakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
PR Newswire
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
PR Newswire
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for High-Need Antimicrobial Infections
PR Newswire
Advertisement|Remove ads.